EXECUTIVE DIRECTIVE No. 20-012

WHEREAS, Coronavirus disease 2019 ("COVID-19") is a contagious, and at times fatal, respiratory disease that is caused by the SARS-COV-2 virus and is responsible for the 2019 novel coronavirus outbreak; and

WHEREAS, on January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a "public health emergency of international concern," which means "an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response," and thereafter raised its global risk assessment of COVID-19 from "high" to "very high"; and

WHEREAS, on January 31, 2020, the Secretary of the United States Department of Health and Human Services declared a public health emergency for the United States to aid the nation's healthcare community in responding to COVID-19; and

WHEREAS, on March 9, 2020, Governor Philip D. Murphy issued Executive Order 103, declaring the existence of a Public Health Emergency, pursuant to the Emergency Health Powers Act, N.J.S.A. 26:13-1 et seq., and a State of Emergency, pursuant to the Disaster Control Act, N.J.S.A. App A:9-33 et seq., in the State of New Jersey for COVID-19; and

WHEREAS, the Public Health Emergency was extended by Governor Murphy under Executive Orders 119 and 138; and

WHEREAS, as of May 12, 2020, the State has approximately 140,743 documented cases of COVID-19 and 9,508 deaths related to COVID-19; and

WHEREAS, the Centers for Disease Control and Prevention (CDC) expects that additional cases of COVID-19 will be identified in the coming days, including more cases in the United States, and that person-to-person spread is likely to continue to occur; and

WHEREAS, under the declared Public Health Emergency, the Commissioner of the Department of Health (Commissioner) is empowered, pursuant to N.J.S.A. 26:13-12, to
take all reasonable and necessary measures to prevent the transmission of infectious disease and apply proper controls and treatment for infectious disease; and

WHEREAS, expansive and extensive testing of individuals for COVID-19 is essential not only for mitigating and controlling the spread of the virus but also to determine the prevalence of the spread of the virus in the State; and

WHEREAS, in order to receive a SARS-COV-2 molecular test to diagnosis COVID-19, a prescription or order for the test must be issued by a healthcare provider authorized to prescribe or order laboratory tests; and

WHEREAS, not all New Jersey residents have a primary healthcare provider and those that do have a primary healthcare provider may be unable to access primary care due to COVID-19; and

WHEREAS, vulnerable populations, such as the homeless and seasonable workers, are among the residents of New Jersey who oftentimes lack access to primary health care, yet are at the greatest risk for contracting COVID-19 and spreading the virus; and

WHEREAS, it is necessary to decrease barriers to SARS-COV-2 testing so that individuals who lack access to primary healthcare and are unable to obtain a prescription for testing are able to obtain testing; and

WHEREAS, the Department of Health has the authority to issue a Standing Order to allow for individuals to obtain testing; and

WHEREAS, to ensure all residents of New Jersey who require SARS-COV-2 testing are able to undergo testing without a prescription or order is necessary and appropriate.

NOW, THEREFORE, I, JUDITH PERSICHILLI, Commissioner of the New Jersey Department of Health, pursuant to the powers afforded to me under the Emergency Health Powers Act, hereby ORDER and DIRECT the following:

1. The Department of Health shall issue a Standing Order allowing for individuals currently residing in New Jersey to receive a SARS-COV-2 molecular test.

2. Any licensed healthcare provider, licensed pharmacist (to the extent authorized by the Department of Law and Public Safety, Division of Consumer Affairs), or trained personnel at a healthcare facility or medically-supervised COVID-19 testing site in the State is authorized to collect and submit for laboratory analysis a SARS-COV-2 molecular test approved by the U.S. Food and Drug Administration (FDA), authorized by the FDA through an Emergency Use Authorization or approved by the New Jersey Clinical Laboratory Improvement Services as permitted by the FDA under the Standing Order.
3. COVID-19 healthcare facilities, pharmacies (to the extent authorized by the Department of Law and Public Safety, Division of Consumer Affairs) and testing sites submitting specimens for SARS-COV-2 molecular testing under the Standing Order are authorized to receive the results of those tests directly from the testing laboratories.

4. Laboratories receiving specimens for SARS-COV-2 molecular testing under the Standing Order shall report the test results directly to the healthcare facility, pharmacy (to the extent authorized by the Department of Law and Public Safety, Division of Consumer Affairs) or COVID-19 testing site that submitted the specimen.

5. Any healthcare provider, licensed pharmacist (to the extent authorized by the Department of Law and Public Safety, Division of Consumer Affairs) or medically-supervised, trained individual authorized to collect specimens for COVID-19 testing who collects a specimen pursuant to the Standing Order shall provide the individual submitting to the test with:

   a. Information on how and when to obtain test results;
   b. Information for contacting the local health official within the jurisdiction where the individual resides;
   c. Information on obtaining follow-up medical care if the individual’s test results are positive for COVID-19, in accordance with guidance as issued and/or amended by CDC and/or the New Jersey Department of Health; and
   d. Information about public health actions such as self-isolation to be taken based upon the individual’s test results.

6. Any healthcare provider, licensed pharmacist (to the extent authorized by the Department of Law and Public Safety, Division of Consumer Affairs) or medically-supervised, trained individual authorized to collect specimens for SARS-COV-2 testing who collects a specimen pursuant to the Standing Order shall follow CDC guidelines for collecting, handling and testing for COVID-19 and in a manner consistent with the test manufacturer’s instructions.

7. In accordance with N.J.A.C. 8:57, laboratories conducting COVID-19 testing pursuant to the Standing Order shall report the testing results into the New Jersey Communicable Disease Reporting and Surveillance System or provide the results to the New Jersey Department of Health in a manner prescribed by the Department.
This Directive shall take effect immediately. The provisions of this Directive shall remain in force and effect for the duration of the public health emergency unless otherwise amended, superseded, or lifted.

Judit Persichilli, R.N., B.S.N., M.A.
Commissioner

Date 5/12/2020